Rob Schultz

Rob Schultz has extensive work experience in the pharmaceutical industry. Rob began their career as a Research Scientist at MURO Pharmaceuticals, Inc. in 1989 and worked there until 1992. Rob then joined GSK, where they held various positions, including Investigator, Research Investigator, and Investigator in Inhalation Product Development, from 1992 to 2004.

In 2004, Rob joined Kos Pharmaceuticals as an Associate Director and later transitioned to Abbott Laboratories in the same role. Rob worked in Associate Director positions at both companies until 2007. During their time at Kos Pharmaceuticals/Abbott Labs, Rob was responsible for CMC development of Pearl Therapeutics' metered dose inhaler (MDI) products.

In 2007, Rob joined Pearl Therapeutics as the Senior Director of Metered Dose Inhaler Development. In this role, they led the global project team for a triple combination MDI project. Rob worked at Pearl Therapeutics until 2017.

Rob's most recent role is at Satsuma Pharmaceuticals, Inc., where they initially served as the Vice President and Head of CMC from 2017 to 2022. Rob was then promoted to Senior Vice President and Head of CMC in June 2022, a position they currently hold.

Overall, Rob Schultz has gained expertise and leadership experience in CMC development, specifically in the development of metered dose inhaler products.

Rob Schultz attended Dartmouth College from 1982 to 1987, where they obtained a Bachelor's degree in Biochemistry.